Literature DB >> 34652608

Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy.

Marco Bontempi1.   

Abstract

The International Normalized Ratio (INR) monitoring is an essential component to manage thrombotic disease therapy. This study presents a semi-empirical model of INR as a function of time and assigned therapy (Warfarin, k-vitamin). With respect to other methodologies, this model is able to describe the INR using a limited number of parameters and is able to describe the time variation of INR described in the literature. The presented methodology showed great accuracy in model calibration [(trueness (precision)]: 0.2% (0.1%) to 1.2% (0.3%) for coagulation factors, from 5% (9%) to 9.7% (12%) for Warfarin-related parameters and 38% (40%) for K-vitamin-related parameters. The latter value was considered acceptable given the assumptions made in the model. It has two other important results: the first is that it was able to correctly estimate INR with respect to daily therapy doses taken from the literature. The second is that it introduces a single numeric semi-empirical parameter that is able to correlate INR/dose response to physiological and environmental condition of patients.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Coagulation; INR; Semi-empirical model; Thrombosis; Warfarin

Mesh:

Substances:

Year:  2021        PMID: 34652608     DOI: 10.1007/s10928-021-09783-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  32 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.

Authors:  James Demetrios Douketis
Journal:  Intern Emerg Med       Date:  2016-10-20       Impact factor: 3.397

3.  The Hip Fracture Patient on Warfarin: Evaluating Blood Loss and Time to Surgery.

Authors:  Matthew R Cohn; Ashley E Levack; Nikunj N Trivedi; Jordan C Villa; David S Wellman; John P Lyden; Dean G Lorich; Joseph M Lane
Journal:  J Orthop Trauma       Date:  2017-08       Impact factor: 2.512

Review 4.  Prediction of warfarin dose: why, when and how?

Authors:  Niclas Eriksson; Mia Wadelius
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

5.  An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture.

Authors:  Maneesh Bhatia; Gautam Talawadekar; Sailendra Parihar; Andrew Smith
Journal:  Ann R Coll Surg Engl       Date:  2010-05-19       Impact factor: 1.891

6.  Enantiomers of warfarin and vitamin K1 metabolism.

Authors:  I A Choonara; B P Haynes; S Cholerton; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 7.  Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.

Authors:  William E Dager
Journal:  Ann Pharmacother       Date:  2011-12-27       Impact factor: 3.154

8.  Anticoagulation management in hip fracture patients on warfarin.

Authors:  Mamun Al-Rashid; Martyn J Parker
Journal:  Injury       Date:  2005-11       Impact factor: 2.586

Review 9.  Point-of-care testing INR: an overview.

Authors:  Doris Barcellona; Lara Fenu; Francesco Marongiu
Journal:  Clin Chem Lab Med       Date:  2017-05-01       Impact factor: 3.694

Review 10.  Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency.

Authors:  Kenneth A Bauer; Tam M Nguyen-Cao; Jeffrey B Spears
Journal:  Ann Pharmacother       Date:  2016-06-08       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.